{"count": 7, "results": [{"_id": "37304218", "pmid": 37304218, "pmcid": "PMC10250823", "title": "Metformin attenuates diabetes-induced osteopenia in rats is associated with down-regulation of the RAGE-JAK2-STAT1 signal axis", "journal": "J Orthop Translat", "authors": ["Lin R", "Xu B", "Ye Z", "Gao Y", "Fang H", "Song J", "Liang D", "Liu L", "Hu Z", "Zhang M", "Wei J", "Deng F", "Zhong X", "Cui L", "Liu Y"], "date": "2023-06-03T00:00:00Z", "doi": "10.1016/j.jot.2023.05.002", "meta_date_publication": "2023 May", "meta_volume": "40", "meta_issue": "", "meta_pages": "37-48", "score": 50257.156, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ attenuates @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@-induced @<m>DISEASE_Bone_Diseases_Metabolic</m> @DISEASE_MESH:D001851 @@@osteopenia@@@ in @SPECIES_10116 @@@rats@@@ is associated with down-regulation of the @GENE_AGER @GENE_81722 @@@RAGE@@@-@GENE_JAK2 @GENE_24514 @@@JAK2@@@-@GENE_STAT1 @GENE_25124 @@@STAT1@@@ signal axis", "citations": {"NLM": "Lin R, Xu B, Ye Z, Gao Y, Fang H, Song J, Liang D, Liu L, Hu Z, Zhang M, Wei J, Deng F, Zhong X, Cui L, Liu Y. Metformin attenuates diabetes-induced osteopenia in rats is associated with down-regulation of the RAGE-JAK2-STAT1 signal axis J Orthop Translat. 2023 May;40():37-48. PMID: 37304218", "BibTeX": "@article{37304218, title={Metformin attenuates diabetes-induced osteopenia in rats is associated with down-regulation of the RAGE-JAK2-STAT1 signal axis}, author={Lin R and Xu B and Ye Z and Gao Y and Fang H and Song J and Liang D and Liu L and Hu Z and Zhang M and Wei J and Deng F and Zhong X and Cui L and Liu Y}, journal={J Orthop Translat}, volume={40}, pages={37-48}}"}}, {"_id": "35452818", "pmid": 35452818, "title": "Metformin treatment is associated with an increase in bone mineral density in type 2 diabetes mellitus patients in China: A retrospective single center study.", "journal": "Diabetes Metab", "authors": ["Sun J", "Liu Q", "He H", "Jiang L", "Lee KO", "Li D", "Ma J"], "date": "2022-09-01T00:00:00Z", "doi": "10.1016/j.diabet.2022.101350", "meta_date_publication": "2022 Sep", "meta_volume": "48", "meta_issue": "5", "meta_pages": "101350", "score": 50252.543, "text_hl": "RESULTS: Overall prevalence of @<m>DISEASE_Bone_Diseases_Metabolic</m> @DISEASE_MESH:D001851 @@@osteopenia@@@ and @DISEASE_Osteoporosis @DISEASE_MESH:D010024 @@@osteoporosis@@@ was 37.4% and 10.3%, and was lower in @SPECIES_9606 @@@patients@@@ on @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (34.6% vs 38.3% and 7.1% vs 11.3%, both p < 0.001). ", "citations": {"NLM": "Sun J, Liu Q, He H, Jiang L, Lee KO, Li D, Ma J. Metformin treatment is associated with an increase in bone mineral density in type 2 diabetes mellitus patients in China: A retrospective single center study. Diabetes Metab. 2022 Sep;48(5):101350. PMID: 35452818", "BibTeX": "@article{35452818, title={Metformin treatment is associated with an increase in bone mineral density in type 2 diabetes mellitus patients in China: A retrospective single center study.}, author={Sun J and Liu Q and He H and Jiang L and Lee KO and Li D and Ma J}, journal={Diabetes Metab}, volume={48}, number={5}, pages={101350}}"}}, {"_id": "36297386", "pmid": 36297386, "pmcid": "PMC9611301", "title": "The Potential Therapeutic Role of Metformin in Diabetic and Non-Diabetic Bone Impairment", "journal": "Pharmaceuticals (Basel)", "authors": ["Mu W", "Liang G", "Feng Y", "Jiang Y", "Qu F"], "date": "2022-10-17T00:00:00Z", "doi": "10.3390/ph15101274", "meta_date_publication": "2022 Oct 17", "meta_volume": "15", "meta_issue": "10", "meta_pages": "", "score": 50250.277, "text_hl": "Taken together, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ is considered as a potential medication for adjuvant therapy in @<m>DISEASE_Bone_Diseases_Metabolic</m> @DISEASE_MESH:D001851 @@@bone metabolic disorders@@@ further to its antidiabetic effect. ", "citations": {"NLM": "Mu W, Liang G, Feng Y, Jiang Y, Qu F. The Potential Therapeutic Role of Metformin in Diabetic and Non-Diabetic Bone Impairment Pharmaceuticals (Basel). 2022 Oct 17;15(10):. PMID: 36297386", "BibTeX": "@article{36297386, title={The Potential Therapeutic Role of Metformin in Diabetic and Non-Diabetic Bone Impairment}, author={Mu W and Liang G and Feng Y and Jiang Y and Qu F}, journal={Pharmaceuticals (Basel)}, volume={15}, number={10}}"}}, {"_id": "31101413", "pmid": 31101413, "title": "Osteoporosis and Osteopenia Among Patients With Type 2 Diabetes Aged >=50: Role of Sex and Clinical Characteristics.", "journal": "J Clin Densitom", "authors": ["Xu H", "Wang Z", "Li X", "Fan M", "Bao C", "Yang R", "Song F", "Xu W", "Qi X"], "date": "2020-01-01T00:00:00Z", "doi": "10.1016/j.jocd.2019.04.004", "meta_date_publication": "2020 Jan-Mar", "meta_volume": "23", "meta_issue": "1", "meta_pages": "29-36", "score": 50247.32, "text_hl": "After adjustment for potential confounders, the results showed that @DISEASE_Overweight @DISEASE_MESH:D050177 @@@overweight@@@ (OR = 0.59; 95% CI, 0.42-0.81) and @DISEASE_Obesity @DISEASE_MESH:D009765 @@@obesity@@@ (OR = 0.35; 95% CI, 0.24-0.50) were related to decreased odds of @DISEASE_Osteoporosis @DISEASE_MESH:D010024 @@@osteoporosis@@@ and @<m>DISEASE_Bone_Diseases_Metabolic</m> @DISEASE_MESH:D001851 @@@osteopenia@@@ in both male and female @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2DM@@@ @SPECIES_9606 @@@patients@@@, poor glycemic control (OR = 1.63; 95% CI, 1.08-2.47) was associated with increased odds of @DISEASE_Osteoporosis @DISEASE_MESH:D010024 @@@osteoporosis@@@ and @<m>DISEASE_Bone_Diseases_Metabolic</m> @DISEASE_MESH:D001851 @@@osteopenia@@@ in males, and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment (OR = 0.65; 95% CI, 0.43-0.99) was associated with decreased odds of @DISEASE_Osteoporosis @DISEASE_MESH:D010024 @@@osteoporosis@@@ and @<m>DISEASE_Bone_Diseases_Metabolic</m> @DISEASE_MESH:D001851 @@@osteopenia@@@ in females. ", "citations": {"NLM": "Xu H, Wang Z, Li X, Fan M, Bao C, Yang R, Song F, Xu W, Qi X. Osteoporosis and Osteopenia Among Patients With Type 2 Diabetes Aged >=50: Role of Sex and Clinical Characteristics. J Clin Densitom. 2020 Jan-Mar;23(1):29-36. PMID: 31101413", "BibTeX": "@article{31101413, title={Osteoporosis and Osteopenia Among Patients With Type 2 Diabetes Aged >=50: Role of Sex and Clinical Characteristics.}, author={Xu H and Wang Z and Li X and Fan M and Bao C and Yang R and Song F and Xu W and Qi X}, journal={J Clin Densitom}, volume={23}, number={1}, pages={29-36}}"}}, {"_id": "31991596", "pmid": 31991596, "pmcid": "PMC7071241", "title": "Acid Hydrolyzed Silk Peptide Consumption Improves Anti-Diabetic Symptoms by Potentiating Insulin Secretion and Preventing Gut Microbiome Dysbiosis in Non-Obese Type 2 Diabetic Animals", "journal": "Nutrients", "authors": ["Park S", "Zhang T", "Qiu JY", "Wu X", "Lee JY", "Lee BY"], "date": "2020-01-24T00:00:00Z", "doi": "10.3390/nu12020311", "meta_date_publication": "2020 Jan 24", "meta_volume": "12", "meta_issue": "2", "meta_pages": "", "score": 50230.434, "text_hl": "In lumbar spines and femurs, the reduction in @<m>DISEASE_Bone_Diseases_Metabolic</m> @DISEASE_MESH:D001851 @@@BMD@@@ during treatment was much greater in the Px-CON group than in the normal-CON group, and these Px-induced @<m>DISEASE_Bone_Diseases_Metabolic</m> @DISEASE_MESH:D001851 @@@BMD@@@ reductions were similarly prevented by SP-H and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (positive-CON; Figure 1A). ", "citations": {"NLM": "Park S, Zhang T, Qiu JY, Wu X, Lee JY, Lee BY. Acid Hydrolyzed Silk Peptide Consumption Improves Anti-Diabetic Symptoms by Potentiating Insulin Secretion and Preventing Gut Microbiome Dysbiosis in Non-Obese Type 2 Diabetic Animals Nutrients. 2020 Jan 24;12(2):. PMID: 31991596", "BibTeX": "@article{31991596, title={Acid Hydrolyzed Silk Peptide Consumption Improves Anti-Diabetic Symptoms by Potentiating Insulin Secretion and Preventing Gut Microbiome Dysbiosis in Non-Obese Type 2 Diabetic Animals}, author={Park S and Zhang T and Qiu JY and Wu X and Lee JY and Lee BY}, journal={Nutrients}, volume={12}, number={2}}"}}, {"_id": "25633418", "pmid": 25633418, "title": "Pathophysiological Mechanism of Bone Loss in Type 2 Diabetes Involves Inverse Regulation of Osteoblast Function by PGC-1alpha and Skeletal Muscle Atrogenes: AdipoR1 as a Potential Target for Reversing Diabetes-Induced Osteopenia.", "journal": "Diabetes", "authors": ["Khan MP", "Singh AK", "Joharapurkar AA", "Yadav M", "Shree S", "Kumar H", "Gurjar A", "Mishra JS", "Tiwari MC", "Nagar GK", "Kumar S", "Ramachandran R", "Sharan A", "Jain MR", "Trivedi AK", "Maurya R", "Godbole MM", "Gayen JR", "Sanyal S", "Chattopadhyay N"], "date": "2015-07-01T00:00:00Z", "doi": "10.2337/db14-1611", "meta_date_publication": "2015 Jul", "meta_volume": "64", "meta_issue": "7", "meta_pages": "2609-23", "score": 50046.83, "text_hl": "Osteoblast-specific @GENE_PPARGC1A @GENE_19017 @@@PGC-1alpha@@@ upregulation by 6-C-beta-d-glucopyranosyl-(2S,3S)-(+)-5,7,3',4'-tetrahydroxydihydroflavonol (GTDF), an @GENE_ADIPOR1 @GENE_72674 @@@adiponectin receptor 1@@@ (@GENE_ADIPOR1 @GENE_72674 @@@AdipoR1@@@) agonist, as well as @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in db @SPECIES_10090 @@@mice@@@ that lacked @GENE_ADIPOR1 @GENE_72674 @@@AdipoR1@@@ expression in muscle but not bone restored @<m>DISEASE_Bone_Diseases_Metabolic</m> @DISEASE_MESH:D001851 @@@osteopenia@@@ to wt levels without improving @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@. ", "citations": {"NLM": "Khan MP, Singh AK, Joharapurkar AA, Yadav M, Shree S, Kumar H, Gurjar A, Mishra JS, Tiwari MC, Nagar GK, Kumar S, Ramachandran R, Sharan A, Jain MR, Trivedi AK, Maurya R, Godbole MM, Gayen JR, Sanyal S, Chattopadhyay N. Pathophysiological Mechanism of Bone Loss in Type 2 Diabetes Involves Inverse Regulation of Osteoblast Function by PGC-1alpha and Skeletal Muscle Atrogenes: AdipoR1 as a Potential Target for Reversing Diabetes-Induced Osteopenia. Diabetes. 2015 Jul;64(7):2609-23. PMID: 25633418", "BibTeX": "@article{25633418, title={Pathophysiological Mechanism of Bone Loss in Type 2 Diabetes Involves Inverse Regulation of Osteoblast Function by PGC-1alpha and Skeletal Muscle Atrogenes: AdipoR1 as a Potential Target for Reversing Diabetes-Induced Osteopenia.}, author={Khan MP and Singh AK and Joharapurkar AA and Yadav M and Shree S and Kumar H and Gurjar A and Mishra JS and Tiwari MC and Nagar GK and Kumar S and Ramachandran R and Sharan A and Jain MR and Trivedi AK and Maurya R and Godbole MM and Gayen JR and Sanyal S and Chattopadhyay N}, journal={Diabetes}, volume={64}, number={7}, pages={2609-23}}"}}, {"_id": "18519839", "pmid": 18519839, "title": "Aggressively managing type 2 diabetes mellitus, hyperlipidemia, and bone loss.", "journal": "J Am Osteopath Assoc", "authors": ["Spellman CW"], "date": "2008-05-01T00:00:00Z", "meta_date_publication": "2008 May", "meta_volume": "108", "meta_issue": "5 Suppl 3", "meta_pages": "S20-7", "score": 50041.695, "text_hl": "He also strongly recommends incorporating nutrition counseling by registered, licensed dietitians and exercise (preferably of a weight-bearing nature) into treatment plans for @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2DM@@@, @DISEASE_Hyperlipidemias @DISEASE_MESH:D006949 @@@hyperlipidemia@@@, and @<m>DISEASE_Bone_Diseases_Metabolic</m> @DISEASE_MESH:D001851 @@@low bone mass@@@.", "citations": {"NLM": "Spellman CW. Aggressively managing type 2 diabetes mellitus, hyperlipidemia, and bone loss. J Am Osteopath Assoc. 2008 May;108(5 Suppl 3):S20-7. PMID: 18519839", "BibTeX": "@article{18519839, title={Aggressively managing type 2 diabetes mellitus, hyperlipidemia, and bone loss.}, author={Spellman CW}, journal={J Am Osteopath Assoc}, volume={108}, number={5 Suppl 3}, pages={S20-7}}"}}]}